May 9, 2022 — Heart failure presents differently in women and men – discover the latest evidence and its impact on management at

Primary tabs View(active tab) Edit Delete Revisions Entityqueue Devel Open configuration options Open configuration options Videos | Venous Therapies | June 27, 2017 VIDEO: How the Ekos Thrombolytic Technology Works to Dissolve Clots Open Related Chest Pain Imaging Content: configuration options Venous Thrombolytic System Demonstration Play Mute Remaining Time -3:23 Picture-in-Picture Fullscreen This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat dee

Here are the top 10 performing videos on the Diagnostic and Interventional Cardiology (DAIC) website during the month of April. The picks are based on Google Analytics of the DAIC website's video pageviews for the month, showing the top viewed content.

1. VIDEO: How the Ekos Thrombolytic Technology Works to Dissolve Clots

May 9, 2022 — CVRx, Inc., developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S.

COVID-19 had a profound impact on the cardiovascular imaging system in 2020.

The global cardiovascular ultrasound systems market was expected to register a CAGR of 5.9% over the forecast period, according to The Cardiovascular Ultrasound System Market—Growth, Trends, COVID-19 Impact and Forecast (2022-2027), a new report f
The trends of an increased interest in RPM and potential cost savings have inspired companies to participate in this slowly evolving paradigm shift and improve technology

I work at Emory University in a multidisciplinary group that is employing medical technologies to improve our understanding of cardiovascular disease autonomic physiology and behavioral mechanisms. We incorporate measurements of physical activity, stress and sleep into our research.

May 5, 2022 – The American Society of Echocardiography (ASE), the largest global organization for cardiovascular ultrasound imaging professionals, will recognize eight award recipients at the

May 5, 2022 – Foldax, Inc. has announced that the first patients have been enrolled in the Drugs Controller General of India (DCGI)-approved clinical trial of the TRIA biopolymer surgical aortic heart valve. The TRIA valve reimagines the heart valve by combining the company’s proprietary biopolymer – LifePolymer – with an innovative valve design intended to resist calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants.

May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial septal defects (ASD), or opening defect in the wall of the heart that separates the top two chambers of the heart, using the first transcatheter ASD occluder with a metal-free frame. The novel device has been implanted as part of the ASCENT ASD U.S.

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).

May 5, 2022 – A new Yale-led study has for the first time identified which risk factors are more likely to trigger a heart attack or acute myocardial infarction (AMI) for men and women 55 years and younger.

Researchers discovered significant sex differences in risk factors associated with AMI and in the strength of associations among young adults, suggesting the need for a sex-specific preventive strategy. For example, hypertension, diabetes, depression, and poverty had stronger associations with AMI in women compared with men, they found.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now